nodes	percent_of_prediction	percent_of_DWPC	metapath
Lansoprazole—Hair disorder—Hydrochlorothiazide—nephrolithiasis	0.0262	0.0439	CcSEcCtD
Lansoprazole—Oral disorder—Hydrochlorothiazide—nephrolithiasis	0.0236	0.0395	CcSEcCtD
Lansoprazole—Abnormal faeces—Hydrochlorothiazide—nephrolithiasis	0.0208	0.0349	CcSEcCtD
Lansoprazole—Blood potassium increased—Hydrochlorothiazide—nephrolithiasis	0.0197	0.033	CcSEcCtD
Lansoprazole—MAPT—nephron tubule—nephrolithiasis	0.0172	0.0803	CbGeAlD
Lansoprazole—CYP2C19—urine—nephrolithiasis	0.0165	0.0774	CbGeAlD
Lansoprazole—MAPT—cortex of kidney—nephrolithiasis	0.0147	0.0687	CbGeAlD
Lansoprazole—ATP4B—Ion channel transport—CLCN5—nephrolithiasis	0.0146	0.0775	CbGpPWpGaD
Lansoprazole—ATP4B—Ion channel transport—CLCN4—nephrolithiasis	0.0146	0.0775	CbGpPWpGaD
Lansoprazole—CYP4A11—renal system—nephrolithiasis	0.0144	0.0672	CbGeAlD
Lansoprazole—CYP4A11—kidney—nephrolithiasis	0.0139	0.065	CbGeAlD
Lansoprazole—CYP4A11—cortex of kidney—nephrolithiasis	0.0135	0.0633	CbGeAlD
Lansoprazole—CYP1A2—urine—nephrolithiasis	0.0135	0.0632	CbGeAlD
Lansoprazole—ATP4A—Ion channel transport—CLCN4—nephrolithiasis	0.013	0.069	CbGpPWpGaD
Lansoprazole—ATP4A—Ion channel transport—CLCN5—nephrolithiasis	0.013	0.069	CbGpPWpGaD
Lansoprazole—CYP2C9—urine—nephrolithiasis	0.0128	0.06	CbGeAlD
Lansoprazole—ATP4A—renal system—nephrolithiasis	0.0116	0.0542	CbGeAlD
Lansoprazole—Epigastric discomfort—Hydrochlorothiazide—nephrolithiasis	0.0113	0.019	CcSEcCtD
Lansoprazole—Anorectal disorder—Hydrochlorothiazide—nephrolithiasis	0.0113	0.019	CcSEcCtD
Lansoprazole—ATP4A—kidney—nephrolithiasis	0.0112	0.0524	CbGeAlD
Lansoprazole—CYP3A4—urine—nephrolithiasis	0.00977	0.0457	CbGeAlD
Lansoprazole—CYP2D6—urine—nephrolithiasis	0.00962	0.045	CbGeAlD
Lansoprazole—Nephritis interstitial—Hydrochlorothiazide—nephrolithiasis	0.00882	0.0148	CcSEcCtD
Lansoprazole—Hyperlipidaemia—Hydrochlorothiazide—nephrolithiasis	0.00826	0.0138	CcSEcCtD
Lansoprazole—Tubulointerstitial nephritis—Hydrochlorothiazide—nephrolithiasis	0.00778	0.013	CcSEcCtD
Lansoprazole—Memory impairment—Hydrochlorothiazide—nephrolithiasis	0.00759	0.0127	CcSEcCtD
Lansoprazole—Glycosuria—Hydrochlorothiazide—nephrolithiasis	0.00735	0.0123	CcSEcCtD
Lansoprazole—Musculoskeletal stiffness—Hydrochlorothiazide—nephrolithiasis	0.00664	0.0111	CcSEcCtD
Lansoprazole—Gout—Hydrochlorothiazide—nephrolithiasis	0.00638	0.0107	CcSEcCtD
Lansoprazole—Musculoskeletal pain—Hydrochlorothiazide—nephrolithiasis	0.00603	0.0101	CcSEcCtD
Lansoprazole—Wheezing—Hydrochlorothiazide—nephrolithiasis	0.00578	0.00968	CcSEcCtD
Lansoprazole—Blood urea increased—Hydrochlorothiazide—nephrolithiasis	0.00562	0.00941	CcSEcCtD
Lansoprazole—Aplastic anaemia—Hydrochlorothiazide—nephrolithiasis	0.00559	0.00936	CcSEcCtD
Lansoprazole—Oesophagitis—Hydrochlorothiazide—nephrolithiasis	0.00544	0.00911	CcSEcCtD
Lansoprazole—Urine output increased—Hydrochlorothiazide—nephrolithiasis	0.00538	0.00901	CcSEcCtD
Lansoprazole—ATP4B—Transmembrane transport of small molecules—CLCN5—nephrolithiasis	0.00509	0.027	CbGpPWpGaD
Lansoprazole—ATP4B—Transmembrane transport of small molecules—CLCN4—nephrolithiasis	0.00509	0.027	CbGpPWpGaD
Lansoprazole—CYP1B1—nephron tubule—nephrolithiasis	0.00507	0.0237	CbGeAlD
Lansoprazole—Sleep disorder—Hydrochlorothiazide—nephrolithiasis	0.00499	0.00836	CcSEcCtD
Lansoprazole—Diabetes mellitus—Hydrochlorothiazide—nephrolithiasis	0.00497	0.00832	CcSEcCtD
Lansoprazole—Polyuria—Hydrochlorothiazide—nephrolithiasis	0.00492	0.00824	CcSEcCtD
Lansoprazole—Photosensitivity—Hydrochlorothiazide—nephrolithiasis	0.00492	0.00824	CcSEcCtD
Lansoprazole—Gastroenteritis—Hydrochlorothiazide—nephrolithiasis	0.00488	0.00816	CcSEcCtD
Lansoprazole—Vascular purpura—Hydrochlorothiazide—nephrolithiasis	0.00483	0.00809	CcSEcCtD
Lansoprazole—Haemolytic anaemia—Hydrochlorothiazide—nephrolithiasis	0.00479	0.00801	CcSEcCtD
Lansoprazole—Injury—Hydrochlorothiazide—nephrolithiasis	0.0047	0.00787	CcSEcCtD
Lansoprazole—Libido decreased—Hydrochlorothiazide—nephrolithiasis	0.00466	0.0078	CcSEcCtD
Lansoprazole—Hot flush—Hydrochlorothiazide—nephrolithiasis	0.00462	0.00773	CcSEcCtD
Lansoprazole—CYP1B1—renal system—nephrolithiasis	0.00461	0.0216	CbGeAlD
Lansoprazole—Increased appetite—Hydrochlorothiazide—nephrolithiasis	0.0046	0.0077	CcSEcCtD
Lansoprazole—Menopausal symptoms—Hydrochlorothiazide—nephrolithiasis	0.00458	0.00767	CcSEcCtD
Lansoprazole—Dermatitis exfoliative—Hydrochlorothiazide—nephrolithiasis	0.00458	0.00767	CcSEcCtD
Lansoprazole—Thirst—Hydrochlorothiazide—nephrolithiasis	0.00454	0.0076	CcSEcCtD
Lansoprazole—Renal impairment—Hydrochlorothiazide—nephrolithiasis	0.00454	0.0076	CcSEcCtD
Lansoprazole—ATP4A—Transmembrane transport of small molecules—CLCN5—nephrolithiasis	0.00454	0.024	CbGpPWpGaD
Lansoprazole—ATP4A—Transmembrane transport of small molecules—CLCN4—nephrolithiasis	0.00454	0.024	CbGpPWpGaD
Lansoprazole—ATP4B—Transmembrane transport of small molecules—SLC26A6—nephrolithiasis	0.00454	0.024	CbGpPWpGaD
Lansoprazole—ABCG2—Iron uptake and transport—ATP6V0A4—nephrolithiasis	0.0045	0.0238	CbGpPWpGaD
Lansoprazole—Purpura—Hydrochlorothiazide—nephrolithiasis	0.00449	0.00751	CcSEcCtD
Lansoprazole—CYP1B1—kidney—nephrolithiasis	0.00446	0.0209	CbGeAlD
Lansoprazole—Arthritis—Hydrochlorothiazide—nephrolithiasis	0.00445	0.00744	CcSEcCtD
Lansoprazole—CYP1B1—cortex of kidney—nephrolithiasis	0.00434	0.0203	CbGeAlD
Lansoprazole—Hyponatraemia—Hydrochlorothiazide—nephrolithiasis	0.00434	0.00726	CcSEcCtD
Lansoprazole—Gastrointestinal haemorrhage—Hydrochlorothiazide—nephrolithiasis	0.00432	0.00724	CcSEcCtD
Lansoprazole—Disturbance in sexual arousal—Hydrochlorothiazide—nephrolithiasis	0.00429	0.00718	CcSEcCtD
Lansoprazole—Affect lability—Hydrochlorothiazide—nephrolithiasis	0.00426	0.00712	CcSEcCtD
Lansoprazole—Migraine—Hydrochlorothiazide—nephrolithiasis	0.00426	0.00712	CcSEcCtD
Lansoprazole—Face oedema—Hydrochlorothiazide—nephrolithiasis	0.00417	0.00699	CcSEcCtD
Lansoprazole—ATP4B—Transmembrane transport of small molecules—SLC34A3—nephrolithiasis	0.00415	0.022	CbGpPWpGaD
Lansoprazole—ATP4B—Transmembrane transport of small molecules—SLC3A1—nephrolithiasis	0.00415	0.022	CbGpPWpGaD
Lansoprazole—Mood swings—Hydrochlorothiazide—nephrolithiasis	0.0041	0.00685	CcSEcCtD
Lansoprazole—Blood creatinine increased—Hydrochlorothiazide—nephrolithiasis	0.00405	0.00678	CcSEcCtD
Lansoprazole—ATP4A—Transmembrane transport of small molecules—SLC26A6—nephrolithiasis	0.00404	0.0214	CbGpPWpGaD
Lansoprazole—Liver function test abnormal—Hydrochlorothiazide—nephrolithiasis	0.00399	0.00668	CcSEcCtD
Lansoprazole—Dry skin—Hydrochlorothiazide—nephrolithiasis	0.00396	0.00663	CcSEcCtD
Lansoprazole—Hypokalaemia—Hydrochlorothiazide—nephrolithiasis	0.00393	0.00659	CcSEcCtD
Lansoprazole—Breast disorder—Hydrochlorothiazide—nephrolithiasis	0.00391	0.00654	CcSEcCtD
Lansoprazole—Aspartate aminotransferase increased—Hydrochlorothiazide—nephrolithiasis	0.00389	0.00652	CcSEcCtD
Lansoprazole—Toxic epidermal necrolysis—Hydrochlorothiazide—nephrolithiasis	0.00389	0.00652	CcSEcCtD
Lansoprazole—Cramp muscle—Hydrochlorothiazide—nephrolithiasis	0.00389	0.00652	CcSEcCtD
Lansoprazole—Gastritis—Hydrochlorothiazide—nephrolithiasis	0.00383	0.0064	CcSEcCtD
Lansoprazole—Alanine aminotransferase increased—Hydrochlorothiazide—nephrolithiasis	0.00381	0.00638	CcSEcCtD
Lansoprazole—Muscular weakness—Hydrochlorothiazide—nephrolithiasis	0.00381	0.00638	CcSEcCtD
Lansoprazole—ABCG2—nephron tubule—nephrolithiasis	0.00378	0.0177	CbGeAlD
Lansoprazole—Abdominal distension—Hydrochlorothiazide—nephrolithiasis	0.00376	0.0063	CcSEcCtD
Lansoprazole—Influenza—Hydrochlorothiazide—nephrolithiasis	0.00374	0.00625	CcSEcCtD
Lansoprazole—Dysphagia—Hydrochlorothiazide—nephrolithiasis	0.00374	0.00625	CcSEcCtD
Lansoprazole—ATP4A—Transmembrane transport of small molecules—SLC34A3—nephrolithiasis	0.0037	0.0196	CbGpPWpGaD
Lansoprazole—ATP4A—Transmembrane transport of small molecules—SLC3A1—nephrolithiasis	0.0037	0.0196	CbGpPWpGaD
Lansoprazole—Pancreatitis—Hydrochlorothiazide—nephrolithiasis	0.00366	0.00613	CcSEcCtD
Lansoprazole—Angina pectoris—Hydrochlorothiazide—nephrolithiasis	0.00364	0.00609	CcSEcCtD
Lansoprazole—CYP2C8—renal system—nephrolithiasis	0.00353	0.0165	CbGeAlD
Lansoprazole—Neutropenia—Hydrochlorothiazide—nephrolithiasis	0.00349	0.00585	CcSEcCtD
Lansoprazole—Dysuria—Hydrochlorothiazide—nephrolithiasis	0.00349	0.00585	CcSEcCtD
Lansoprazole—Upper respiratory tract infection—Hydrochlorothiazide—nephrolithiasis	0.00347	0.00581	CcSEcCtD
Lansoprazole—Pollakiuria—Hydrochlorothiazide—nephrolithiasis	0.00345	0.00578	CcSEcCtD
Lansoprazole—Erectile dysfunction—Hydrochlorothiazide—nephrolithiasis	0.00344	0.00576	CcSEcCtD
Lansoprazole—CYP2C8—kidney—nephrolithiasis	0.00341	0.016	CbGeAlD
Lansoprazole—Photosensitivity reaction—Hydrochlorothiazide—nephrolithiasis	0.00341	0.00571	CcSEcCtD
Lansoprazole—Weight increased—Hydrochlorothiazide—nephrolithiasis	0.0034	0.00569	CcSEcCtD
Lansoprazole—Hyperglycaemia—Hydrochlorothiazide—nephrolithiasis	0.00337	0.00564	CcSEcCtD
Lansoprazole—Pneumonia—Hydrochlorothiazide—nephrolithiasis	0.00335	0.00561	CcSEcCtD
Lansoprazole—CYP1A2—renal system—nephrolithiasis	0.0033	0.0155	CbGeAlD
Lansoprazole—Stevens-Johnson syndrome—Hydrochlorothiazide—nephrolithiasis	0.0033	0.00553	CcSEcCtD
Lansoprazole—Acute coronary syndrome—Hydrochlorothiazide—nephrolithiasis	0.00328	0.0055	CcSEcCtD
Lansoprazole—Renal failure—Hydrochlorothiazide—nephrolithiasis	0.00327	0.00548	CcSEcCtD
Lansoprazole—Myocardial infarction—Hydrochlorothiazide—nephrolithiasis	0.00327	0.00547	CcSEcCtD
Lansoprazole—Neuropathy peripheral—Hydrochlorothiazide—nephrolithiasis	0.00327	0.00547	CcSEcCtD
Lansoprazole—CYP1A1—renal system—nephrolithiasis	0.00326	0.0153	CbGeAlD
Lansoprazole—Jaundice—Hydrochlorothiazide—nephrolithiasis	0.00325	0.00544	CcSEcCtD
Lansoprazole—CYP4A11—NRF2 pathway—SLC2A9—nephrolithiasis	0.00324	0.0172	CbGpPWpGaD
Lansoprazole—Urinary tract infection—Hydrochlorothiazide—nephrolithiasis	0.00324	0.00542	CcSEcCtD
Lansoprazole—Conjunctivitis—Hydrochlorothiazide—nephrolithiasis	0.00324	0.00542	CcSEcCtD
Lansoprazole—Sweating—Hydrochlorothiazide—nephrolithiasis	0.00319	0.00535	CcSEcCtD
Lansoprazole—Haematuria—Hydrochlorothiazide—nephrolithiasis	0.00318	0.00532	CcSEcCtD
Lansoprazole—CYP1A1—kidney—nephrolithiasis	0.00315	0.0147	CbGeAlD
Lansoprazole—ATP4B—Transmembrane transport of small molecules—SLC22A12—nephrolithiasis	0.00315	0.0167	CbGpPWpGaD
Lansoprazole—ATP4B—Transmembrane transport of small molecules—SLC34A1—nephrolithiasis	0.00315	0.0167	CbGpPWpGaD
Lansoprazole—Epistaxis—Hydrochlorothiazide—nephrolithiasis	0.00314	0.00526	CcSEcCtD
Lansoprazole—Sinusitis—Hydrochlorothiazide—nephrolithiasis	0.00313	0.00523	CcSEcCtD
Lansoprazole—Agranulocytosis—Hydrochlorothiazide—nephrolithiasis	0.00311	0.0052	CcSEcCtD
Lansoprazole—Bradycardia—Hydrochlorothiazide—nephrolithiasis	0.00304	0.0051	CcSEcCtD
Lansoprazole—Rhinitis—Hydrochlorothiazide—nephrolithiasis	0.003	0.00502	CcSEcCtD
Lansoprazole—Hepatitis—Hydrochlorothiazide—nephrolithiasis	0.00299	0.00501	CcSEcCtD
Lansoprazole—Hypoaesthesia—Hydrochlorothiazide—nephrolithiasis	0.00298	0.00498	CcSEcCtD
Lansoprazole—Pharyngitis—Hydrochlorothiazide—nephrolithiasis	0.00297	0.00497	CcSEcCtD
Lansoprazole—Oedema peripheral—Hydrochlorothiazide—nephrolithiasis	0.00295	0.00493	CcSEcCtD
Lansoprazole—ATP4B—Transmembrane transport of small molecules—SLC2A9—nephrolithiasis	0.00292	0.0155	CbGpPWpGaD
Lansoprazole—ATP4B—Transmembrane transport of small molecules—SLC26A1—nephrolithiasis	0.00292	0.0155	CbGpPWpGaD
Lansoprazole—Visual impairment—Hydrochlorothiazide—nephrolithiasis	0.00288	0.00482	CcSEcCtD
Lansoprazole—CYP4A11—Biological oxidations—SLC26A1—nephrolithiasis	0.00284	0.015	CbGpPWpGaD
Lansoprazole—Erythema multiforme—Hydrochlorothiazide—nephrolithiasis	0.00283	0.00473	CcSEcCtD
Lansoprazole—ATP4A—Transmembrane transport of small molecules—SLC34A1—nephrolithiasis	0.0028	0.0148	CbGpPWpGaD
Lansoprazole—ATP4A—Transmembrane transport of small molecules—SLC22A12—nephrolithiasis	0.0028	0.0148	CbGpPWpGaD
Lansoprazole—Tinnitus—Hydrochlorothiazide—nephrolithiasis	0.00279	0.00467	CcSEcCtD
Lansoprazole—Arrhythmia—Hydrochlorothiazide—nephrolithiasis	0.00267	0.00447	CcSEcCtD
Lansoprazole—Alopecia—Hydrochlorothiazide—nephrolithiasis	0.00264	0.00442	CcSEcCtD
Lansoprazole—ATP4B—Transmembrane transport of small molecules—ATP6V0A4—nephrolithiasis	0.00261	0.0138	CbGpPWpGaD
Lansoprazole—ATP4A—Transmembrane transport of small molecules—SLC26A1—nephrolithiasis	0.00261	0.0138	CbGpPWpGaD
Lansoprazole—ATP4A—Transmembrane transport of small molecules—SLC2A9—nephrolithiasis	0.00261	0.0138	CbGpPWpGaD
Lansoprazole—ATP4B—Transmembrane transport of small molecules—SLC7A9—nephrolithiasis	0.00261	0.0138	CbGpPWpGaD
Lansoprazole—Erythema—Hydrochlorothiazide—nephrolithiasis	0.0026	0.00436	CcSEcCtD
Lansoprazole—Flatulence—Hydrochlorothiazide—nephrolithiasis	0.00257	0.00429	CcSEcCtD
Lansoprazole—Tension—Hydrochlorothiazide—nephrolithiasis	0.00255	0.00428	CcSEcCtD
Lansoprazole—Dysgeusia—Hydrochlorothiazide—nephrolithiasis	0.00255	0.00427	CcSEcCtD
Lansoprazole—Nervousness—Hydrochlorothiazide—nephrolithiasis	0.00253	0.00423	CcSEcCtD
Lansoprazole—Back pain—Hydrochlorothiazide—nephrolithiasis	0.00252	0.00421	CcSEcCtD
Lansoprazole—Muscle spasms—Hydrochlorothiazide—nephrolithiasis	0.0025	0.00419	CcSEcCtD
Lansoprazole—CYP2C18—Biological oxidations—SLC26A1—nephrolithiasis	0.00248	0.0132	CbGpPWpGaD
Lansoprazole—Vision blurred—Hydrochlorothiazide—nephrolithiasis	0.00245	0.00411	CcSEcCtD
Lansoprazole—Tremor—Hydrochlorothiazide—nephrolithiasis	0.00244	0.00408	CcSEcCtD
Lansoprazole—Ill-defined disorder—Hydrochlorothiazide—nephrolithiasis	0.00242	0.00404	CcSEcCtD
Lansoprazole—Anaemia—Hydrochlorothiazide—nephrolithiasis	0.00241	0.00403	CcSEcCtD
Lansoprazole—Agitation—Hydrochlorothiazide—nephrolithiasis	0.00239	0.004	CcSEcCtD
Lansoprazole—CYP3A4—renal system—nephrolithiasis	0.00239	0.0112	CbGeAlD
Lansoprazole—Angioedema—Hydrochlorothiazide—nephrolithiasis	0.00238	0.00398	CcSEcCtD
Lansoprazole—CYP2D6—renal system—nephrolithiasis	0.00235	0.011	CbGeAlD
Lansoprazole—Malaise—Hydrochlorothiazide—nephrolithiasis	0.00235	0.00393	CcSEcCtD
Lansoprazole—Vertigo—Hydrochlorothiazide—nephrolithiasis	0.00234	0.00391	CcSEcCtD
Lansoprazole—Syncope—Hydrochlorothiazide—nephrolithiasis	0.00233	0.00391	CcSEcCtD
Lansoprazole—Leukopenia—Hydrochlorothiazide—nephrolithiasis	0.00233	0.0039	CcSEcCtD
Lansoprazole—ATP4A—Transmembrane transport of small molecules—ATP6V0A4—nephrolithiasis	0.00232	0.0123	CbGpPWpGaD
Lansoprazole—ATP4A—Transmembrane transport of small molecules—SLC7A9—nephrolithiasis	0.00232	0.0123	CbGpPWpGaD
Lansoprazole—CYP3A4—kidney—nephrolithiasis	0.00231	0.0108	CbGeAlD
Lansoprazole—Palpitations—Hydrochlorothiazide—nephrolithiasis	0.0023	0.00385	CcSEcCtD
Lansoprazole—Loss of consciousness—Hydrochlorothiazide—nephrolithiasis	0.00229	0.00383	CcSEcCtD
Lansoprazole—CYP2D6—kidney—nephrolithiasis	0.00227	0.0106	CbGeAlD
Lansoprazole—Cough—Hydrochlorothiazide—nephrolithiasis	0.00227	0.0038	CcSEcCtD
Lansoprazole—Arthralgia—Hydrochlorothiazide—nephrolithiasis	0.00222	0.00371	CcSEcCtD
Lansoprazole—Myalgia—Hydrochlorothiazide—nephrolithiasis	0.00222	0.00371	CcSEcCtD
Lansoprazole—Chest pain—Hydrochlorothiazide—nephrolithiasis	0.00222	0.00371	CcSEcCtD
Lansoprazole—Anxiety—Hydrochlorothiazide—nephrolithiasis	0.00221	0.0037	CcSEcCtD
Lansoprazole—Discomfort—Hydrochlorothiazide—nephrolithiasis	0.00219	0.00367	CcSEcCtD
Lansoprazole—Dry mouth—Hydrochlorothiazide—nephrolithiasis	0.00217	0.00363	CcSEcCtD
Lansoprazole—Confusional state—Hydrochlorothiazide—nephrolithiasis	0.00214	0.00359	CcSEcCtD
Lansoprazole—Oedema—Hydrochlorothiazide—nephrolithiasis	0.00212	0.00356	CcSEcCtD
Lansoprazole—Anaphylactic shock—Hydrochlorothiazide—nephrolithiasis	0.00212	0.00356	CcSEcCtD
Lansoprazole—Shock—Hydrochlorothiazide—nephrolithiasis	0.00209	0.0035	CcSEcCtD
Lansoprazole—ATP4B—Transmembrane transport of small molecules—AQP1—nephrolithiasis	0.00208	0.011	CbGpPWpGaD
Lansoprazole—Thrombocytopenia—Hydrochlorothiazide—nephrolithiasis	0.00208	0.00348	CcSEcCtD
Lansoprazole—Tachycardia—Hydrochlorothiazide—nephrolithiasis	0.00207	0.00347	CcSEcCtD
Lansoprazole—Hyperhidrosis—Hydrochlorothiazide—nephrolithiasis	0.00205	0.00344	CcSEcCtD
Lansoprazole—Anorexia—Hydrochlorothiazide—nephrolithiasis	0.00203	0.00339	CcSEcCtD
Lansoprazole—Hypotension—Hydrochlorothiazide—nephrolithiasis	0.00199	0.00332	CcSEcCtD
Lansoprazole—Musculoskeletal discomfort—Hydrochlorothiazide—nephrolithiasis	0.00194	0.00324	CcSEcCtD
Lansoprazole—Insomnia—Hydrochlorothiazide—nephrolithiasis	0.00192	0.00322	CcSEcCtD
Lansoprazole—Paraesthesia—Hydrochlorothiazide—nephrolithiasis	0.00191	0.00319	CcSEcCtD
Lansoprazole—Dyspnoea—Hydrochlorothiazide—nephrolithiasis	0.00189	0.00317	CcSEcCtD
Lansoprazole—Somnolence—Hydrochlorothiazide—nephrolithiasis	0.00189	0.00316	CcSEcCtD
Lansoprazole—Dyspepsia—Hydrochlorothiazide—nephrolithiasis	0.00187	0.00313	CcSEcCtD
Lansoprazole—ABCB1—nephron tubule—nephrolithiasis	0.00186	0.00871	CbGeAlD
Lansoprazole—ATP4A—Transmembrane transport of small molecules—AQP1—nephrolithiasis	0.00186	0.00983	CbGpPWpGaD
Lansoprazole—Decreased appetite—Hydrochlorothiazide—nephrolithiasis	0.00185	0.00309	CcSEcCtD
Lansoprazole—Fatigue—Hydrochlorothiazide—nephrolithiasis	0.00183	0.00307	CcSEcCtD
Lansoprazole—CYP1B1—Biological oxidations—SLC26A1—nephrolithiasis	0.00183	0.0097	CbGpPWpGaD
Lansoprazole—Pain—Hydrochlorothiazide—nephrolithiasis	0.00182	0.00304	CcSEcCtD
Lansoprazole—Constipation—Hydrochlorothiazide—nephrolithiasis	0.00182	0.00304	CcSEcCtD
Lansoprazole—Feeling abnormal—Hydrochlorothiazide—nephrolithiasis	0.00175	0.00293	CcSEcCtD
Lansoprazole—Gastrointestinal pain—Hydrochlorothiazide—nephrolithiasis	0.00174	0.00291	CcSEcCtD
Lansoprazole—ABCB1—renal system—nephrolithiasis	0.00169	0.00792	CbGeAlD
Lansoprazole—Urticaria—Hydrochlorothiazide—nephrolithiasis	0.00169	0.00283	CcSEcCtD
Lansoprazole—Abdominal pain—Hydrochlorothiazide—nephrolithiasis	0.00168	0.00281	CcSEcCtD
Lansoprazole—Body temperature increased—Hydrochlorothiazide—nephrolithiasis	0.00168	0.00281	CcSEcCtD
Lansoprazole—MAPT—BDNF signaling pathway—SPP1—nephrolithiasis	0.00167	0.00886	CbGpPWpGaD
Lansoprazole—ABCB1—kidney—nephrolithiasis	0.00164	0.00766	CbGeAlD
Lansoprazole—ABCB1—cortex of kidney—nephrolithiasis	0.00159	0.00746	CbGeAlD
Lansoprazole—Hypersensitivity—Hydrochlorothiazide—nephrolithiasis	0.00157	0.00262	CcSEcCtD
Lansoprazole—Asthenia—Hydrochlorothiazide—nephrolithiasis	0.00152	0.00255	CcSEcCtD
Lansoprazole—Pruritus—Hydrochlorothiazide—nephrolithiasis	0.0015	0.00252	CcSEcCtD
Lansoprazole—Diarrhoea—Hydrochlorothiazide—nephrolithiasis	0.00145	0.00243	CcSEcCtD
Lansoprazole—Dizziness—Hydrochlorothiazide—nephrolithiasis	0.00141	0.00235	CcSEcCtD
Lansoprazole—Vomiting—Hydrochlorothiazide—nephrolithiasis	0.00135	0.00226	CcSEcCtD
Lansoprazole—Rash—Hydrochlorothiazide—nephrolithiasis	0.00134	0.00224	CcSEcCtD
Lansoprazole—Dermatitis—Hydrochlorothiazide—nephrolithiasis	0.00134	0.00224	CcSEcCtD
Lansoprazole—Headache—Hydrochlorothiazide—nephrolithiasis	0.00133	0.00223	CcSEcCtD
Lansoprazole—Nausea—Hydrochlorothiazide—nephrolithiasis	0.00126	0.00211	CcSEcCtD
Lansoprazole—CYP1A2—Phase II conjugation—SLC26A1—nephrolithiasis	0.00123	0.00651	CbGpPWpGaD
Lansoprazole—CYP1A1—Biological oxidations—SLC26A1—nephrolithiasis	0.00113	0.00597	CbGpPWpGaD
Lansoprazole—ABCG2—Transmembrane transport of small molecules—CLCN4—nephrolithiasis	0.00106	0.00561	CbGpPWpGaD
Lansoprazole—ABCG2—Transmembrane transport of small molecules—CLCN5—nephrolithiasis	0.00106	0.00561	CbGpPWpGaD
Lansoprazole—CYP2C8—Biological oxidations—SLC26A1—nephrolithiasis	0.00103	0.00547	CbGpPWpGaD
Lansoprazole—ABCG2—Transmembrane transport of small molecules—SLC26A6—nephrolithiasis	0.000944	0.005	CbGpPWpGaD
Lansoprazole—CYP2C19—Biological oxidations—SLC26A1—nephrolithiasis	0.000923	0.00489	CbGpPWpGaD
Lansoprazole—ABCG2—Transmembrane transport of small molecules—SLC34A3—nephrolithiasis	0.000863	0.00457	CbGpPWpGaD
Lansoprazole—ABCG2—Transmembrane transport of small molecules—SLC3A1—nephrolithiasis	0.000863	0.00457	CbGpPWpGaD
Lansoprazole—CYP2D6—Biological oxidations—SLC26A1—nephrolithiasis	0.000849	0.00449	CbGpPWpGaD
Lansoprazole—CYP2C9—Biological oxidations—SLC26A1—nephrolithiasis	0.000841	0.00446	CbGpPWpGaD
Lansoprazole—CYP1A2—Biological oxidations—SLC26A1—nephrolithiasis	0.000719	0.00381	CbGpPWpGaD
Lansoprazole—ABCG2—Transmembrane transport of small molecules—SLC34A1—nephrolithiasis	0.000654	0.00346	CbGpPWpGaD
Lansoprazole—ABCG2—Transmembrane transport of small molecules—SLC22A12—nephrolithiasis	0.000654	0.00346	CbGpPWpGaD
Lansoprazole—CYP4A11—Metabolism—GRHPR—nephrolithiasis	0.000641	0.0034	CbGpPWpGaD
Lansoprazole—ABCG2—Transmembrane transport of small molecules—SLC26A1—nephrolithiasis	0.000608	0.00322	CbGpPWpGaD
Lansoprazole—ABCG2—Transmembrane transport of small molecules—SLC2A9—nephrolithiasis	0.000608	0.00322	CbGpPWpGaD
Lansoprazole—ABCB1—Transmembrane transport of small molecules—CLCN5—nephrolithiasis	0.000573	0.00303	CbGpPWpGaD
Lansoprazole—ABCB1—Transmembrane transport of small molecules—CLCN4—nephrolithiasis	0.000573	0.00303	CbGpPWpGaD
Lansoprazole—CYP4A11—Metabolism—AGXT—nephrolithiasis	0.000572	0.00303	CbGpPWpGaD
Lansoprazole—CYP2C18—Metabolism—GRHPR—nephrolithiasis	0.000561	0.00297	CbGpPWpGaD
Lansoprazole—CYP3A4—Biological oxidations—SLC26A1—nephrolithiasis	0.000555	0.00294	CbGpPWpGaD
Lansoprazole—ABCG2—Transmembrane transport of small molecules—ATP6V0A4—nephrolithiasis	0.000542	0.00287	CbGpPWpGaD
Lansoprazole—ABCG2—Transmembrane transport of small molecules—SLC7A9—nephrolithiasis	0.000542	0.00287	CbGpPWpGaD
Lansoprazole—ABCB1—Transmembrane transport of small molecules—SLC26A6—nephrolithiasis	0.00051	0.0027	CbGpPWpGaD
Lansoprazole—CYP2C18—Metabolism—AGXT—nephrolithiasis	0.0005	0.00265	CbGpPWpGaD
Lansoprazole—CYP4A11—Metabolism—APRT—nephrolithiasis	0.000486	0.00257	CbGpPWpGaD
Lansoprazole—CYP4A11—Metabolism—SLC26A1—nephrolithiasis	0.000486	0.00257	CbGpPWpGaD
Lansoprazole—ABCB1—Transmembrane transport of small molecules—SLC34A3—nephrolithiasis	0.000467	0.00247	CbGpPWpGaD
Lansoprazole—ABCB1—Transmembrane transport of small molecules—SLC3A1—nephrolithiasis	0.000467	0.00247	CbGpPWpGaD
Lansoprazole—ABCG2—Transmembrane transport of small molecules—AQP1—nephrolithiasis	0.000433	0.0023	CbGpPWpGaD
Lansoprazole—CYP2C18—Metabolism—SLC26A1—nephrolithiasis	0.000425	0.00225	CbGpPWpGaD
Lansoprazole—CYP2C18—Metabolism—APRT—nephrolithiasis	0.000425	0.00225	CbGpPWpGaD
Lansoprazole—CYP1B1—Metabolism—GRHPR—nephrolithiasis	0.000413	0.00219	CbGpPWpGaD
Lansoprazole—ABCG2—Metabolism—GRHPR—nephrolithiasis	0.000376	0.00199	CbGpPWpGaD
Lansoprazole—CYP1B1—Metabolism—AGXT—nephrolithiasis	0.000368	0.00195	CbGpPWpGaD
Lansoprazole—ABCB1—Transmembrane transport of small molecules—SLC34A1—nephrolithiasis	0.000354	0.00187	CbGpPWpGaD
Lansoprazole—ABCB1—Transmembrane transport of small molecules—SLC22A12—nephrolithiasis	0.000354	0.00187	CbGpPWpGaD
Lansoprazole—CYP4A11—Metabolism—AQP1—nephrolithiasis	0.000346	0.00183	CbGpPWpGaD
Lansoprazole—ABCG2—Metabolism—AGXT—nephrolithiasis	0.000335	0.00177	CbGpPWpGaD
Lansoprazole—ABCB1—Transmembrane transport of small molecules—SLC26A1—nephrolithiasis	0.000329	0.00174	CbGpPWpGaD
Lansoprazole—ABCB1—Transmembrane transport of small molecules—SLC2A9—nephrolithiasis	0.000329	0.00174	CbGpPWpGaD
Lansoprazole—CYP1B1—Metabolism—APRT—nephrolithiasis	0.000313	0.00166	CbGpPWpGaD
Lansoprazole—CYP1B1—Metabolism—SLC26A1—nephrolithiasis	0.000313	0.00166	CbGpPWpGaD
Lansoprazole—CYP4A11—Metabolism—CHRM3—nephrolithiasis	0.000313	0.00166	CbGpPWpGaD
Lansoprazole—CYP2C18—Metabolism—AQP1—nephrolithiasis	0.000303	0.0016	CbGpPWpGaD
Lansoprazole—ABCB1—Transmembrane transport of small molecules—SLC7A9—nephrolithiasis	0.000293	0.00155	CbGpPWpGaD
Lansoprazole—ABCB1—Transmembrane transport of small molecules—ATP6V0A4—nephrolithiasis	0.000293	0.00155	CbGpPWpGaD
Lansoprazole—ABCG2—Metabolism—APRT—nephrolithiasis	0.000285	0.00151	CbGpPWpGaD
Lansoprazole—ABCG2—Metabolism—SLC26A1—nephrolithiasis	0.000285	0.00151	CbGpPWpGaD
Lansoprazole—CYP2C18—Metabolism—CHRM3—nephrolithiasis	0.000274	0.00145	CbGpPWpGaD
Lansoprazole—CYP1A1—Metabolism—GRHPR—nephrolithiasis	0.000254	0.00135	CbGpPWpGaD
Lansoprazole—ABCB1—Transmembrane transport of small molecules—AQP1—nephrolithiasis	0.000234	0.00124	CbGpPWpGaD
Lansoprazole—CYP2C8—Metabolism—GRHPR—nephrolithiasis	0.000233	0.00124	CbGpPWpGaD
Lansoprazole—CYP1A1—Metabolism—AGXT—nephrolithiasis	0.000227	0.0012	CbGpPWpGaD
Lansoprazole—CYP1B1—Metabolism—AQP1—nephrolithiasis	0.000223	0.00118	CbGpPWpGaD
Lansoprazole—CYP2C19—Metabolism—GRHPR—nephrolithiasis	0.000208	0.0011	CbGpPWpGaD
Lansoprazole—CYP2C8—Metabolism—AGXT—nephrolithiasis	0.000208	0.0011	CbGpPWpGaD
Lansoprazole—ABCB1—Metabolism—GRHPR—nephrolithiasis	0.000203	0.00108	CbGpPWpGaD
Lansoprazole—ABCG2—Metabolism—AQP1—nephrolithiasis	0.000203	0.00107	CbGpPWpGaD
Lansoprazole—CYP1B1—Metabolism—CHRM3—nephrolithiasis	0.000202	0.00107	CbGpPWpGaD
Lansoprazole—CYP1A1—Metabolism—SLC26A1—nephrolithiasis	0.000193	0.00102	CbGpPWpGaD
Lansoprazole—CYP1A1—Metabolism—APRT—nephrolithiasis	0.000193	0.00102	CbGpPWpGaD
Lansoprazole—CYP2D6—Metabolism—GRHPR—nephrolithiasis	0.000192	0.00101	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism—GRHPR—nephrolithiasis	0.00019	0.00101	CbGpPWpGaD
Lansoprazole—CYP2C19—Metabolism—AGXT—nephrolithiasis	0.000186	0.000983	CbGpPWpGaD
Lansoprazole—ABCG2—Metabolism—CHRM3—nephrolithiasis	0.000184	0.000972	CbGpPWpGaD
Lansoprazole—ABCB1—Metabolism—AGXT—nephrolithiasis	0.000181	0.000959	CbGpPWpGaD
Lansoprazole—CYP2C8—Metabolism—APRT—nephrolithiasis	0.000177	0.000936	CbGpPWpGaD
Lansoprazole—CYP2C8—Metabolism—SLC26A1—nephrolithiasis	0.000177	0.000936	CbGpPWpGaD
Lansoprazole—CYP2D6—Metabolism—AGXT—nephrolithiasis	0.000171	0.000904	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism—AGXT—nephrolithiasis	0.000169	0.000896	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism—GRHPR—nephrolithiasis	0.000162	0.000859	CbGpPWpGaD
Lansoprazole—CYP2C19—Metabolism—SLC26A1—nephrolithiasis	0.000158	0.000836	CbGpPWpGaD
Lansoprazole—CYP2C19—Metabolism—APRT—nephrolithiasis	0.000158	0.000836	CbGpPWpGaD
Lansoprazole—ABCB1—Metabolism—SLC26A1—nephrolithiasis	0.000154	0.000816	CbGpPWpGaD
Lansoprazole—ABCB1—Metabolism—APRT—nephrolithiasis	0.000154	0.000816	CbGpPWpGaD
Lansoprazole—CYP2D6—Metabolism—SLC26A1—nephrolithiasis	0.000145	0.000769	CbGpPWpGaD
Lansoprazole—CYP2D6—Metabolism—APRT—nephrolithiasis	0.000145	0.000769	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism—AGXT—nephrolithiasis	0.000145	0.000766	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism—APRT—nephrolithiasis	0.000144	0.000762	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism—SLC26A1—nephrolithiasis	0.000144	0.000762	CbGpPWpGaD
Lansoprazole—CYP1A1—Metabolism—AQP1—nephrolithiasis	0.000137	0.000728	CbGpPWpGaD
Lansoprazole—CYP2C8—Metabolism—AQP1—nephrolithiasis	0.000126	0.000667	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—GRHPR—nephrolithiasis	0.000125	0.000663	CbGpPWpGaD
Lansoprazole—CYP1A1—Metabolism—CHRM3—nephrolithiasis	0.000124	0.000658	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism—APRT—nephrolithiasis	0.000123	0.000651	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism—SLC26A1—nephrolithiasis	0.000123	0.000651	CbGpPWpGaD
Lansoprazole—CYP2C8—Metabolism—CHRM3—nephrolithiasis	0.000114	0.000603	CbGpPWpGaD
Lansoprazole—CYP2C19—Metabolism—AQP1—nephrolithiasis	0.000112	0.000595	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—AGXT—nephrolithiasis	0.000112	0.000591	CbGpPWpGaD
Lansoprazole—ABCB1—Metabolism—AQP1—nephrolithiasis	0.00011	0.000581	CbGpPWpGaD
Lansoprazole—CYP2D6—Metabolism—AQP1—nephrolithiasis	0.000103	0.000548	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism—AQP1—nephrolithiasis	0.000103	0.000543	CbGpPWpGaD
Lansoprazole—CYP2C19—Metabolism—CHRM3—nephrolithiasis	0.000102	0.000538	CbGpPWpGaD
Lansoprazole—ABCB1—Metabolism—CHRM3—nephrolithiasis	9.93e-05	0.000526	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—SLC26A1—nephrolithiasis	9.49e-05	0.000503	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—APRT—nephrolithiasis	9.49e-05	0.000503	CbGpPWpGaD
Lansoprazole—CYP2D6—Metabolism—CHRM3—nephrolithiasis	9.35e-05	0.000495	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism—CHRM3—nephrolithiasis	9.27e-05	0.000491	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism—AQP1—nephrolithiasis	8.76e-05	0.000464	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism—CHRM3—nephrolithiasis	7.92e-05	0.00042	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—AQP1—nephrolithiasis	6.76e-05	0.000358	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—CHRM3—nephrolithiasis	6.12e-05	0.000324	CbGpPWpGaD
